Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SVRA vs BCAX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SVRA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–1 Matrix Metrics)

SVRA Overall Winner 6-Pillar Tally: SVRA 3 – 2 BCAX (1 Tie) Matrix Metrics: SVRA 6 – 1 BCAX

As of Nov 16, 2026, Savara Inc. (SVRA) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). SVRA carries a Unified Composite Score of 55.6/100 (HOLD) at $4.46 (0.4x Forward P/E, 0.0% operating margin), whereas BCAX carries 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: SVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.6); meanwhile BCAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SVRA vs BCAX
SVRA NASDAQ Head-to-Head Winner
Savara Inc.
Pharmaceutical Preparations
$4.46
-3.77% 1D
Market Cap $1.0B
TTM Revenue $1,000
Forward P/E 0.4x
Beta / 30D Vol 1.47β · 73% Vol
Unified Composite Score
55.6 / 100 HOLD
Tech 30.0 Fund 54.0 Flow 70.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.8%), weak momentum, RSI 42
RSI-14: 41.6 · SMA20: $4.72 · SMA50: $4.92
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $665.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.42β · 184% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.1%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $11.85 · SMA50: $16.57

6-Pillar Scorecard Institutional Category Breakdown (SVRA 3 – 2 BCAX)

Columns: Metric · SVRA · BCAX
1. Valuation Multiples SVRA
Forward P/E 0.4x N/M
Trailing P/E 0.4x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale SVRA
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1,000 N/A
Market Cap $1.0B $665.2M
3. Profitability & Quality BCAX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -151.0% -54.2%
4. Balance Sheet & Cash Flow BCAX
Cash Generation (TTM) -$131M -$163M
Cash Flow Margin N/A N/A
Net Cash / Leverage $551,000 Net Debt (0.28x D/E) $81M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SVRA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 164.3% (17th %ile) 102.7% (23rd %ile)
Put/Call OI Skew 0.05x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SVRA (6) vs BCAX (1)
Institutional Metric SVRA BCAX Criterion Row Edge
Market Capitalization
Scale
$1.0B $665.2M Larger Scale SVRA
Trailing P/E Ratio
Valuation
0.4x N/M Lower Multiple SVRA
Forward P/E Ratio
Valuation
0.4x N/M Lower Multiple SVRA
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-151.0% -54.2% Higher ROE BCAX
52-Week Range Position
Momentum
15% ($4–$7) 8% ($8–$31) Stronger Trend SVRA
Beta / 30D Volatility
Risk Regime
1.47β · 73% Vol 1.42β · 184% Vol Lower Realized Risk SVRA
Unified Institutional Score
Composite Signal
55.6 / 100 (HOLD) 52.1 / 100 (HOLD) Higher Composite SVRA
Trailing 12M Revenue (USD)
Operating Scale
$1,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$131M ($551,000 Net Debt (0.28x D/E)) -$163M ($81M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SVRA +42.24 pp
SVRA: +0.34% · BCAX: -41.9%
3M Horizon SVRA +44.02 pp
SVRA: -16.85% · BCAX: -60.87%
6M Horizon SVRA +40.4 pp
SVRA: -9.06% · BCAX: -49.46%
1Y Horizon SVRA +36.44 pp
SVRA: +4.81% · BCAX: -31.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SVRA vs BCAX. Trailing 12-month operating profitability (SVRA 0.0% vs BCAX 0.0%) and valuation multiples (SVRA 0.4x vs BCAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SVRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-151.0% · 0.4x
BCAX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-54.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SVRA BREAKDOWN
92d in phase · OBV ACCUMULATION
Current IV 164.3%
IV Percentile 17th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BCAX BREAKDOWN
93d in phase · OBV ACCUMULATION
Current IV 102.7%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact BCAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SVRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BCAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $665.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SVRA vs BCAX Key Questions & Quantitative Answers

As of Nov 16, 2026, Savara Inc. (SVRA) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). SVRA carries a Unified Composite Score of 55.6/100 (HOLD) at $4.46 (0.4x Forward P/E, 0.0% operating margin), whereas BCAX carries 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.6); meanwhile BCAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SVRA leads the Growth & Scale pillar: SVRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with BCAX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SVRA generates $1,000 in USD-normalized revenue versus N/A for BCAX. In operating R&D and SG&A reinvestment, SVRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BCAX.

SVRA screens cheaper on headline valuation multiples. SVRA trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas BCAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SVRA (-151.0% ROE) versus BCAX (-54.2% ROE) capital efficiency.

In options market volatility and institutional positioning, SVRA carries 164.3% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 73% Vol realized risk). By comparison, BCAX carries 102.7% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 184% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.